Nuo Therapeutics, Inc. (AURX) SEC Filing 8-K Material Event for the period ending Friday, November 15, 2019

Nuo Therapeutics, Inc.

CIK: 1091596 Ticker: AURX

View differences made from one to another to evaluate Nuo Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Nuo Therapeutics, Inc..


Assess how Nuo Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Nuo Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


Ticker: AURX
CIK: 1091596
Form Type: 8-K Corporate News
Accession Number: 0001437749-19-023291
Submitted to the SEC: Wed Nov 20 2019 4:30:42 PM EST
Accepted by the SEC: Wed Nov 20 2019
Period: Friday, November 15, 2019
Industry: Surgical And Medical Instruments And Apparatus
  1. Financial Exhibit
  2. New Agreement
  3. New Financial Obligation
  4. Unregistered Sales

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: